VERTEX PHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss

The total revenue of VX1 for the last quarter is 2.35 B CHF, and it's 0.72% lower compared to the previous quarter. The net income of Q3 24 is 885.90 M CHF.